6634 ªYÄ£
ªÑ¥»: 3.832»õ
¥Dn·~°È:
¨xŦ¯e¯fªvÀø¤Î¯kµhªvÀø¬ÛÃöÃĪ«¬ã¨s¤Î¶}µo
¸³ºÊ«ùªÑ¤ñ¨Ò: 21.7%(¼W¥[¤¤)
¥~¸ê«ùªÑ¤ñ¨Ò: 0.22%(¼W¥[¤¤)
Ä~Äò©¹¤U¬Ý...!
=============================================================================
²£«~01¡GSNP-610 (ªvÀø¯×ªÕ¨x¯e¯f·sÃÄ)
¾AÀ³¯g: «D°sºë©Ê¯×ªÕ¨xª¢
²£«~Àu¶Õ:
1.¥Ø«e©|µL¼Ð·ÇªvÀøÃĪ«
2.¥«³õº¨£·sÃÄ(First-in-class)
3.¦P®É¥i¥Î©ó°sºë©Ê©M«D°sºë©Ê¯×ªÕ¨x
4.µL¦w¥þ©Ê°ÝÃD
¥«³õ: «D°sºë©Ê¯×ªÕ¨xª¢¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸¡C
Ävª§¤O:
1.¦h«§@¥Î¾÷Âà:ªvÀø¤Î¹w¨¾¯×ªÕ¨xª¢
2.ª½±µ§@¥Î©ó¨xŦ¡AªvÀø¯×ªÕ¨xª¢¡A°§C¨x¯×
3.¥i´£¥X¨uÃĥӽСAÀ³¥Î©óªvÀø§³®W«æ©Ê¯×ªÕ¨x
¬ãµo¶¥¬q:
1.¤w³q¹LUSFDA¤ÎTFDA¼f¬d¶i¤JÁ{§É¤G´Á
2.Á{§ÉÀø®Ä¤Î·sªvÀø¾÷ÂàÅçÃÒ
Àø®Ä¤ÀªR¡G
1.²Ä¤@´ÁÁ{§É¸ÕÅç¡Gµ²ªGÅã¥Ü¤HÅé¨Ï¥Î¦w¥þ¡A©Ê½è¨}¦n
2.²Ä¤G´ÁÁ{§É¸ÕÅç¨ä¤¤¤ÀªR¡G17¦ìNASH ¯f¤H (p=0.009)
=============================================================================
²£«~02¡GSNP-630
¾AÀ³¯g:«D°sºë©Ê¯×ªÕ¨xª¢
²£«~Àu¶Õ:
1.¬°Àu¤Æ(Optimized)¤§·s¤Æ¾Ç¹êÅé(NCE)
2.¥«³õº¨£·sÃÄ(First-in-class)
3.¦P®É¥i¥Î©ó°sºë©Ê©M«D°sºë©Ê¯×ªÕ¨x
4.§@¬°²Ä¤@¥N²£«~¤W¥««áªº±µÄò¦û¦³¥«³õ¤§²£«~
¥«³õ: «D°sºë©Ê¯×ªÕ¨xª¢¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸¡C
Ävª§¤O:
1.¦h«§@¥Î¾÷Âà:ªvÀø¤Î¹w¨¾¯×ªÕ¨xª¢
2.ª½±µ§@¥Î©ó¨xŦ¡AªvÀø¯×ªÕ¨xª¢¡A°§C¨x¯×
3.Àu¤ÆªºÀø®Ä±j«×¡B§@¥Î®É¶¡
4.µL¦w¥þ©Ê°ÝÃD
¬ãµo¶¥¬q:
1.Á{§É«e
2.¹w©w¥Ó½Ð¬ü°êFDAIND¡B§Ö³t³q¹D(fasttrack)¡C
3.¥Ó½Ð¬ü°ê¬ð¯}©ÊªvÀø(breakthrough therapy)ªº»{©w¡C
Àø®Ä¤ÀªR¡G
1. ¥Ø«e¦b°Êª«¤W¥H¤£¦P¾¯¶q¶i¦æ¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.05
=============================================================================
²£«~03¡GSNP-810 (µL¨x¬r©Ê¤îµh·sÃÄ¡B¸Ñ¬r¾¯)
¾AÀ³¯g: µL¨x¬r©Ê¤AñQÓi×ô¤îµhÃÄ (¸Ñ¼öÂíµh¾¯)
²£«~Àu¶Õ:
1.¦w¥þ¤Æ¦Xª«·s²Õ¦X¡BµL¨x¬r©Ê
2.¸Ñ¨M¢¤ÁÂåÀø»Ý¨D (Important urgent unmet medical needs)
3.¦³¾¯«¬±M§Q¡A¦w¥þ½d³ò¤j¡A¥i×§ï©Î§R°£FDA¨x¬rĵ»y¥i¼W¥[¾¯¶q
¥«³õ: ¤AñQÓi×ô¶È¦b¬ü°ê¤@¦~´N¦³40»õ¬ü¤¸ªº¥«³õ
Ävª§¤O:
1.¥«³õ¤WµLÃþ¦üµL¨x¬r©Ê¤§Ävª§ÃĪ«
2.¥i§ð¦û¼s¤j¥«³õ¡]NSAID, COX-2 §í¨î¾¯¡BOpioidsÃþ¤îµhÃÄ¥«³õ¡^
3.¥i¬Ù°£¶D³^¶O¡B±Ð¨|°V½m¶O
¬ãµo¶¥¬q:
1.¤w§¹¦¨§C¾¯¶q¡B°ª¾¯¶qÁ{§É¸ÕÅç
2.¤w¥Ó½ÐUSFDA¼Ï纽Á{§É¸ÕÅç¡B±N¥Ó½Ð¬ð¯}©Ê¼f¬d/§Ö³t³q¹D
3.µL¨x¬r©Ê¤AñQÓi×ô¸Ñ¬r¾¯¦¨¤À¡A¤w¥Ó½Ð¬dÅçµn°O¥Î¤§Á{§É¸ÕÅç
=============================================================================
²£«~04¡GSNP-830/ SNP-840
¾AÀ³¯g: µL¨x¬r©Ê¤AñQÓi×ô¤îµhÃĽƤè(ªvÀø¤¤¡B««×¯kµh)
²£«~Àu¶Õ:
1.µL¨x¬r©Ê¤AñQÓi×ôªº½Æ¤è
2.¦³¾¯«¬±M§Q¡A¦w¥þ½d³ò¤j¡A¥i×§ï©Î§R°£FDA¨x¬rĵ»y¡A¥i¼W¥[¾¯¶q
¥«³õ: ¤AñQÓi×ô³B¤èÃĦb¬ü°ê¤@¦~´N¦³27»õ¬ü¤¸ªº¥«³õ
Ävª§¤O:
1.¥«³õ¤WµLÃþ¦üµL¨x¬r©Ê¤§Ävª§ÃĪ«½Æ¤è
2.½Æ¤è¤w¥Ñ¬ü°êFDAn¨D°¾¯¶q§C©ó325²@§J¡A±N¼vÅTÀø®Ä
3.¦³¨Ï¥Î±M§Q¡A¥i×§ï©Î§R°£FDA¨x¬rĵ»y
4.¥i¼W¥[¤AñQÓi×ô¾¯¶q
¡]¥Ñ325mg ¦^´_¦Ü500 mg¬Æ¦Ü§ó°ª¡A·|¸û¦³®Ä¡^¥H¼W¥[Àø®Ä¡A©Î´î¤ÖOpioids¾¯¶q¡A°§C¦¨Å}°Æ§@¥Î
5.¤GªÌ¾Ü¤@±ÂÅv
6.¥i¼W¥[¥«¦û²v
¬ãµo¶¥¬q:
1.SNP-810¨ú±oÃÄÃÒ«á¡A¶i¦æÁ{§É¸ÕÅç§t¬Ûµ¥©Ê¸ÕÅç
SNP-830 ¤£¬O ·s¦¨¤À ªº·sÃÄ¡A©Ò¥H¤£»Ýn¶i¦æ²Ä¤@¡A¤G¤Î¤T´ÁÁ{§É´úÅç
µ¥ SNP-810 ®³¨ìÃÄÃÒ«á¡A¥H ·sÀø®Ä½Æ¤è¶i¦æÁ{§É¸ÕÅç§t¬Ûµ¥©Ê´úÅç ´N¥i¥HÀò±oÃÄÃÒ
=============================================================================
*****************************************************************************
SNP-8 ¨t¦C Àø®Ä¤ÀªR¡G
1. ¦b°Êª«¤W¥H¤£¦P¾¯¶q¶i¦æ¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.005
1. ¤w¸g§¹¦¨¤§¤HÅé¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.005
=============================================================================
*****************************************************************************
¥¼¨Ó¥Ø¼Ð±ÂÅv¥D¤O²£«~¡G
1. ¯×ªÕ¨xÃÄ¡GSNP-610 ©M SNP-630 ¦U¦³ÀuÂI¡A¥Ø¼Ð¬°¥þ²y±ÂÅv
2. ¤îµhÃÄ(OTC): SNP-810, ¥Ø¼Ð¬°¬ü°ê¤Î¥þ²y±ÂÅv
3. ¤îµhÃÄ(³B¤èÃÄ): SNP-830 ¤Î SNP-840, ¦b°Êª«¤W¬Ò¦³¥¿±ªºµ²ªG¡A¥Ø¼Ð¬°¥þ²y±ÂÅv
=============================================================================
*****************************************************************************
¥Ø«e¤½¥q»P°ê»Ú¤j«¬Ãļt¥¿¦b½Í§Þ³N±ÂÅv©M¦X§@p¹º
§Ú¬Ý¹L¤½¥q©xºô©M©Ò´£¨Ñªº¸ê®Æ¡Aı±o¤½¥q«Ü¥Î¤ß¦b¸gÀç¡A¦Ó¥B¸ê®Æ¤]«Ü¸Ô²Ó
¹ï¤½¥qµo®i«Ü¦³¦Û«H¡A¥¼¨ÓªÑ»ùȱo´Á«Ý¡A¦³¾÷·|¬O ¤U¤@Ó ¦X¤@ ÄÆªÑ
-----------------------------------------------------------------------------
¥H¤W¸ê®Æ ³£°Ñ¦Ò ªÑªF·|ij¨Æ¿ý.pdf ©M ¤½¥q©xºô (¦³¿³½ìµÛÅwªï¦A²`¤J¬ã¨s»P°Q½×)
MASHÃĪ«Ävª§ªÌ¦h¡A¥i¯à5¦~¤º·|·s¼W´X¤ä¤W¥«·sÃÄ¡A¦ý³ÌÃø°Ùªº¡§µw°©ÀY¡¨-F4ªì´Á¨xµw¤Æ(¥NÀv¨xµw¤Æ)¤~¬O³Ì¤jªºÂê÷®w!
2025.2.11--§¨Ó¥¸ 6.25»õ¬ü¤¸Äâ¤âÁú°êOlix §ðMASH siRNAÀøªk(Á{§É¤@´Á¤¤)
2024.4.22-¦ÊÆF¨Î¡]Boehringer Ingelheim¡^»P½ê¥Û¥ÍÂå¹F¦¨¨óij...3500 ¸U¬ü¤¸ªº¹w¥I´Ú.»ùȶW¹L10»õ¬ü
¤¸ªº¦X§@¨óij¡A¦@¦P¬ãµoªvÀøºC©Ê¨x¯f¡]CLDs¡^¡A¨Ò¦p¥NÁ©ʯתըxª¢¡]MASH¡^¨xµw¤Æªº²Ä¤@½u³Ð·s¦A
¥ÍÀøªk¡C
2024.1.4-¦ÊÆF¨Î®ï®æ¿« 20»õ¬ü¤¸Äâ¤â¤¤°ê·ç³ÕsiRNAÀøªk§ðNASH
--------------------------------------------------------------------------------------
¥H¤W4¥ó¬O2024~2025¦~MASHÃĪ«¦X§@±ÂÅv®×(©Î¦³¿òº|¨S¦C)
...3.[ÄAÂЦʦ~»{ª¾]½×¤åµoªí:HSCªº«DÅÖºû¤Æ¥\¯à¤~¬Oºû«ù¨xŦúAªºÃöÁä....
---------------------------------------------------------------------
ªYÄ£¥h¦~²Ä8©¡¯×ªÕ¨xª¢ÃĪ«¶}µo°ª®p·|¸ê®Æ
Multiple Effects of SNP-6 series in MASH
www.sinewpharma.com/Upload/download/20240923-SINEW.pdf
¤@¼Ë¼C«üHSC¬¡¤Æ-½¦ì³J¥Õ¨I¿n[§ÜÅÖºû¤Æ]¡A¦ôp¦¹¨è¥¿¥[§Ö±´¨s[ÄAÂЦʦ~»{ª¾]½×¤åªº[HSC«DÅÖºû¤Æ¥\¯à]¾÷¨î!
-----------------------------------------
±q¦L«×µoªíªº¤þ¨xªv¡«áªº [¥¢¥NÀv¨xµw¤Æ]±wªÌ¼Æ¾Ú¡A
¤£½×½Ö®a¥ý®³¨ìMASH[¥NÀv¨xµw¤Æ]F4ÃÄÃÒ¡A«áÄò´N·|¬D¾Ô [¥¢¥NÀv¨xµw¤Æ]±ß´ÁÃÄÃÒ!
³Ìªñ¦L«×ªº¤@¶µHCV(C¨x/¤þ¨x)§Ü¯f¬rªvÀø¬ã¨sªí©ú¡A¦³¨Ç[¥¢¥NÀv¨xµw¤Æ]F4±ß´Á±wªÌ¦bªv¡«á¤]¥i¥H«ì´_¦¨[¥NÀv¨xµw¤Æ]F4ªì´Á!
2024.3.25-www.sciencedirect.com/science/article/abs/pii/S0016508524053599
¤wÃÒ©ú¡A¹ï HCV ¶i¦æ¦³®ÄªvÀø¥i¨Ï¨xµw¤ÆÁ{§É¶¥¬q®ø°h¡A¨ä¤¤¤À§O¦³ 36% ©M 39% ¹F¨ì Child A ©M B ª¬ºA¡C
-----------------------------------------------------------------------------------------
¤þ«¬¨xª¢¯f¬r(HCV¡^·P¬V¨x²ÓM¡A³z¹L¬¡¤Æ¨x¬Pª¬²ÓM¡]HSC¡^©M¨x²Õ´¤¤²ÓM¥~°ò½èªº¹L«×¨I¿n¡A«P¶i¨xÅÖºû¤Æ¡C
¨xµw¤ÆªºÁ{§É¯fµ{¥i¤À¬°¨âÓ¶¥¬q¡A²Ä¤@¶¥¬qºÙ¬°¥NÀv©Ê¡]Child-Pugh A¯Å¡^¡A²Ä¤G¶¥¬q«h¬O¥¢¥NÀv©Ê¡]Child-Pugh B¡BC¯Å¡^¡C
¥Ø«e(CYP2E1§í¨î--->¿E¬¡PPAR£\<--->¿E¬¡FGF21)³o±ø³q¹D¥i¯à´N¬ONASH¦¨¥\¤§¸ô!?
-------------------------------------------------------------------------------------
1.2020¦~¦L«×®Öã¥þ²yº´ÚNASHªvÀø·sÃÄSaroglitazar¦b[¦L«×¤W¥«].
2. ¦Ü¤Ö3¤äFGF21ÃĪ«Á{§É¼Æ¾Ú¤£¿ù¡A2025¦~5¤ëGSKªá20»õ¬ü¤¸¶R¤H³yFGF21Ãþ¦üÃĪ«¡C
3.[ÄAÂЦʦ~»{ª¾]½×¤åµoªí:HSCªº«DÅÖºû¤Æ¥\¯à¤~¬Oºû«ù¨xŦúAªºÃöÁä¡A±NHSC¥¿Å±qÅÖºû¤ÆÂà¦V¨xŦ¦A¥Í«OÅ@¥Nªí¤@ºØ[·s¿oªº¾ãÅéªvÀø¤èªk]¡C¦p¦P±NNASH§ó¦W¬°MASH[¥NÁÂ¥\¯à»Ùê]¬ÛÃö¯×ªÕ©Ê¨xª¢ªº¨º¯ë¡AªÈ¥¿¾ÉP¯e¯fªº¼ç¦b [¥NÁ¯¿¶Ã] ¦ü¥G³Ì¦³Àø®Ä¡A¦Ó¤£¬Oª½±µ¹v¦V±þ¦ºHSC¬¡¤Æ©MÅÖºû¤Æµ¥¦]¤l¡C
journals.plos.org/plosone/article?id=10.1371/journal.pone.0082159
HSC¬OÃþµø¶À»ÄÀx¦sªº¥Dn³¡¦ì¡A¥Í²z¤W³B©óÀR¤îª¬ºA¡A¦b¨x·l¶Ë´Á¶¡¡A³y¦å·F²ÓM·|³vº¥³Q¿E¬¡¡AÄÀ©ñÃþµø¶À»Ä¡A¨ÃÀò±o¦Ù¦¨ÅÖºû²ÓM¼ËªºÅÖºû¤Æ¡B¦¬ÁY©M¼W´Þªí«¬¡C¦b²ÓM°ö¾i¤¤¡AHSC ¥i¥H¹ê²{³oºØ³v¨B¿E¬¡¡A±qÀR¤îª¬ºA¡]°ªÃþµø¶À¾J¤ô¥©M µL£\-SMAªí¹F¡^¸g¹L´ç¿E¬¡ª¬ºA¡]¤¤µ¥Ãþµø¶À¾J©M £\-SMAªí¹F¡^¦A¨ì°ª«×¿E¬¡ª¬ºA¡]§C©ÎµLÃþµø¶À¾J¤ô¥©M°ª£\-SMAªí¹F¡^
--------------------------------------------------------------------------------------
·|û:ROGER588910148151µoªí®É¶¡:2025/5/10 ¤U¤È 11:54:29²Ä4059½g¦^À³
ßߤ§¤¤¦Û¦³¤Ñ·N¡A¤@½g[ÄAÂЦʦ~»{ª¾]½×¤å·|µ¹ªYÄ£(SNP-6§í¨îcyp2e1»PTGF-£])±a¨ÓÅå³ß¶Ü?
¦h¶µ¬ã¨sªí©úcyp2e1¹Lªí¹F¬¡¤ÆHSCs
------------------------------------------------------------------------------------
...(HSCs°ª«×´I¶°RSPO3¡AHSCsªº«DÅÖºû¤Æ¥\¯à¤~¬Oºû«ù¨xŦúAªºÃöÁä¡ARSPO3ªºªí¹F¦bHSCs¬¡¤Æ®É´î¤Ö
-----------------------------------------------------------------------------------------
·|û:ROGER588910148151µoªí®É¶¡:2023/7/31 ¤W¤È 09:41:30²Ä3340½g¦^À³
¦^ÀY¦A¬Ý¼w°ê®ü¼w³ù¤j¾Çªñ40¦~¨Óªº¬ã¨s¡A¯S§O¦³·PCYP2E1©M¨xÅÖºû¤Æµ{«×¤§¶¡¦s¦b[°ª«×ÅãµÛ]ªº¬ÛÃö©Ê!(ªYÄ£F4¥[ªo)
SNP-630§í¨îÅÖºû¤ÆACTA2(£\-SMA)°ò¦]ªí¹F: P<0.0001
SNP-630§í¨îÅÖºû¤ÆTIMP-1°ò¦]ªí¹F:P<0.01
¤HÅé80%ªººû¥Í¯ÀAÀx¦s¦b¨xŦ¨x¬Pª¬²ÓMHSC
¤ô¥¡C
2.¥Ñ©ó¨ã¦³¦¨Å}©Ê¡A±wªÌ¥u¯àµu®É¶¡ªA¥ÎCMZ ¡C
CMZ ¦b 10 ¤Ñ¤º¹ï CYP2E1 ªº§í»s§@¥Î³q¹L £\ °Êû¨x¯×ªÕ©M°§C¦å²MÂà®ò酶¬¡©ÊÅãµÛ§ïµ½¤F ALD¡C
CMZ ¦b 10 ¤Ñ¤º¹ï CYP2E1 ªº§í»s§@¥Î³q¹L £\ °Êû¨x¯×ªÕ©M°§C¦å²MÂà®ò酶¬¡©ÊÅãµÛ§ïµ½¤F ALD¡C
------------------------------------------------------------------------------------
ªYÄ£SNP-6ªº§C°Æ§@¥Î¤]¨S¦³¦¨Å}©Ê°ÝÃD¡A±wªÌ¥iªø®É¶¡ªA¥Î!!!
ªYÄ£SNP-6¦¨¥\²v¦A¸õ°ª!
----------------------------------------------------------------------------------------
ROGER588910148151 µoªí®É¶¡:2022/10/29 ¤U¤È 06:17:24²Ä 2646 ½g¦^À³
¼Ú·ùÁ{§É¸ÕÅçµù¥U www.clinicaltrialsregister.eu/ctr-search/trial/2012-005730-11/DE
¼w°êCMZ(CYP2E1§í»s¾¯)Á{§É¸ÕÅçÅãµÛ§ïµ½¤FALD°sºë©Ê¨xª¢¡A¦ý¬O[¥Ñ©óCMZ¨ã¦³¦¨Å}©Ê¡A¦]¦¹¤£¯àªø´ÁªA¥Î¡C]
------------------------------------------------------------------------------------------
2022.3¤ë30¤é °sºë©Ê¨x¯f±Ô¨Æ¦^ÅU¡G±qÅÖºû¤Æ¨ìÀù¯g
...ªñ 40 ¦~¨Ó¡A§Ú̹êÅç«Ç¤@ª½¦b¬ã¨s²ÓM¦â¯À P4502E1 (CYP2E1) ¦b ALD ©M°sºë¤¶¾ÉªºPÀù§@¥Î¤¤ªº§@¥Î¡C¦¹¥~¡ACYP2E1 ¦b ALE ¤¤ªº§@¥Î¦b CYP2E1 ºV°£¤p¹«¤¤±o¨ì¤F¥O¤H¦L¶H²`¨èªºÃÒ©ú¡A¤£¶ÈÅã¥Ü¥XºC©Ê¶¼°s«á®ñ¤ÆÀ³¿E¼Ð»xª«ªºÅãµÛ°§C¡A¦Ó¥BÁÙÅã¥Ü¥X¨xŦ²Õ´¾ÇªºÅãµÛ§ïµ½ ¡C¥t¤@¤è±¡A¹L«×ªí¹F CYP2E1 ªº°Êª«ªí²{¥X ALD ªºÄY«µ{«×¼W¥[ ¡CCMZ¡]¤@ºØ¯S²§©Ê CYP2E1 §í»s¾¯¡^¹ï CYP2E1 ªº§í¨î¤]§ïµ½¤F°Êª«¹êÅ礤ªº ALD ¡C
³o¥O¤H«HªA¦a±j½Õ¤F CYP2E1 ¦bPÀù§@¥Î¤¤ªº§@¥Î¡C
----------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2023/5/25 ¤U¤È 06:24:07²Ä 3223 ½g¦^À³
³Ì«á¡A³Ìªñªº¤@¶µÀH¾÷Á{§É¸ÕÅç¥O¤H«HªA¦aÃÒ©ú¡ACMZ ¦b 10 ¤Ñ¤º¹ï CYP2E1 ªº§í»s§@¥Î³q¹L £\ °Êû¨x¯×ªÕ©M°§C¦å²MÂà®ò酶¬¡©ÊÅãµÛ§ïµ½¤F ALD¡C
2022.12.22
academic.oup.com/alcalc/article-abstract/58/2/134/6957276?redirectedFrom=fulltext
¤èªk
¶}©ñ¼ÐÅÒ¡BÀH¾÷¹ï·ÓÁ{§É¸ÕÅç¡A¦®¦b¬ã¨s CYP2E1 §í¨î¬O§_¯à§ïµ½±µ¨ü°sºë¸Ñ¬rªvÀø (ADT) ªº°sºë¨Ï¥Î»Ùê±wªÌªº ALD¡C¤J°|®É±wªÌªº¦å²M¤Ñ¥V®ò»Ä®ò°òÂಾ酶 (AST) ¬¡©Ê¥²¶·¶W¹L¥¿±`¤Wªº¨â¿¡A¨Ã¥B®Ú¾ÚÅÖºû±½´yÈ <12 kPa ©w¸q¬°«D¨xµw¤Æ¡C60 ¦W±wªÌ¥H 1:1 ªº¤ñ¨Ò³QÀH¾÷¤À°t¨ì¨Ï¥Î CMZ ©Î´â©Ô¦è¯S (CZP) ¶i¦æ 7-10 ¤Ñªº ADT¡CCYP2E1 ¬¡©Êªº´âÐü¨F©v´ú¸Õ¦b¤J²Õ®É©M¬ã¨s´Á¶¡ªº¨âӮɶ¡ÂI¶i¦æ¡C
µ²ªG
ADT ÅãµÛ§ïµ½¤F¨â²Õªº¨x¯×ªÕÅܩʡ]¨ü±±°I´î°Ñ¼Æ¡^¡C »P CZP ²Õ¡]- 13.9%¡F273 ¡Ó 38 dB/m ¹ï¤ñ 317 ¡Ó 39 dB/m¡FP < 0.0001¡^¡C ¥¿¦p¤w¸g³ø¾Éªº¨º¼Ë¡A»P¦í°|µ²§ô®ÉªA¥Î CZP ªº±wªÌ¬Û¤ñ¡ACMZ ±wªÌªº¦å²M AST ( P < 0.004) ©M¤þ®ò»Ä®ò°òÂಾ酶 (ALT) ¬¡©Ê ( P < 0.0006) ÅãµÛ°§C¡Cµo²{ AST ( P = 0.023)¡BALT ( P = 0.009)¡BGGT ( P = 0.039) ©M CAP ¤§¶¡¦s¦bÅãµÛ¬ÛÃö©Ê¡C
µ²½×:³o¶µ¬ã¨sªí©ú¡ACMZ §ïµ½¤F¤HÃþ ALD ªºÁ{§É¥Íª«¼Ð»xª«¡A³o«Ü¥i¯à¬O¥Ñ©ó¨ä¹ï CYP2E1 ªº§í»s§@¥Î¡C¥Ñ©ó¨ã¦³¦¨Å}©Ê¡ACMZ ¥u¯àµu®É¶¡ªA¥Î¡A¦]¦¹»Ýn¨ä¥L CYP2E1 §í»s¾¯¨ÓªvÀø ALD¡C
Nature¡G颠ÂЦʦ~认ª¾¡I¨x脏纤维¤Æ¤¸¤¿³º¬O¥N谢¦A¥Í总«ü挥
¦b°Êª«¹êÅ礤¡A§½³¡ª`®gRSPO3©`¦ÌÁû²É¨ÏCCl4·l¶Ë¤p¹«ªº [¦A¥Í³t«×]´£¤É2.3¿¡A³oÓ¬ð¯}¬°¨x°IºÜªvÀø±a¨Ó¤F¥þ·s¥i¯à¡C
---------------------------------------------------------------------------------
ROGER588910148151µoªí®É¶¡:2025/5/24 ¤U¤È 12:39:59²Ä4120½g¦^À³
¦³½ìªº¬O¡A¬ã¨sÆ[¹î¨ìCYP2E1§í¨î¥i¥H [¥[³t]AILI(APAP»¤¾É©Ê¨x·l¶Ë)±ß´Áªº [¨xŦ«ì´_]¡C
¦ýµ²½×¥u¬Oªì¨Bªº¡A¨xŦ¦A¥Í¥Íª«¼Ð°OªºÅܤƤ´¦³«Ý¶i¤@¨B½T©w¡C
---------------------------------------------------------------------------------
±N HSC ¥¿Å±qÅÖºû¤ÆÂà¦V¨xŦ«OÅ@¥i¯à¥Nªí¤@ºØ·s¿oªº¾ãÅéªvÀø¤èªk
CYP2E1§í¨î¥[³t¨xŦ«ì´_¡A±N¨x·l¶ËÂà¦V¨xŦ«OÅ@?(SNP-610»PSNP-630ÃĪ«?)
1.¤@¸s´¿³QÂå¾Ç¬É§¯Å]¤Æªº²ÓM¡A³º¬O¾Þ±±¨xŦ©R¹BªºÁô§Î¾Þ½L¤â¡C
¤HÅ餺ªºÅܧΪ÷è¡GHSCsªº´¼¼z¤Á´«¼Ò¦¡
ÃöÁä½Õ±±¸`ÂI¥]¬A¡G TGF-£]3¥i¨ÏHSCsªºRSPO3¤Àªc´î¤Ö92% / ºû¥Í¯ÀAÀx¦s¶q§C©óìHȮɡAHSCs¦Û°Ê¶i¤J
ÅÖºû¤Æ¼Ò¦¡
³o¨Çµo²{¬°¶}µo´¼¼z«¬ÃĪ«´£¨Ñ¤FÂŹϡG³z¹Lºû«ùHSCsªººû¥Í¯ÀAÀx³Æ¡A©Î³\¯àªø´Á«O«ù¨ä×´_¥\¯à¦Ó¤£¤Þµo
ÅÖºû¤Æ¡C
2. pubmed.ncbi.nlm.nih.gov/23543859/
CYP2E1±Nµø¶À»Ä©Mµø¶À¾J°¸Ñ¬°·¥©Ê¥NÁª«¡A¥NÁ¾ÉPµø¶À»Äªº¬y¥¢....
....¸g¹L 10 Ӥ몺ªvÀø¡A¤j¹«¦]°sºë¦Ó°§Cªº¨xŦµø¶À¾J©Mµø¶À»Ä¿@«×³z¹L CMZ(cyp2e1§í¨î¾¯)ªvÀø«ì´_¨ì¥¿±`¤ô¥¡C
--------------------------------------------------------------------------------------
·|û:ROGER588910148151µoªí®É¶¡:2025/5/10 ¤U¤È 11:54:29²Ä4059½g¦^À³
ßߤ§¤¤¦Û¦³¤Ñ·N¡A¤@½g[ÄAÂЦʦ~»{ª¾]½×¤å·|µ¹ªYÄ£(SNP-6§í¨îcyp2e1»PTGF-£])±a¨ÓÅå³ß¶Ü?
2025.4.1--¬ü°êªk°|»é¦^±j¥Í(JNJ.US)100»õ¬ü¤¸À¦¨à²n¨¯»©M¸Ñ¨óij
¬ü°ê¯}²£ªk°|»é¦^±j¥Í¤½¥q(JNJ.US)´£¥Xªº100»õ¬ü¤¸©M¸Ñ´£Ä³¡A¥H²×¤î¼Æ¥H¸Up«ü±±¨äÀ¦¨à¯»¤Î¨ä¥L·Æ¥Û¯»²£«~·|¾ÉP§Z±_Àùªº¶D³^¡A¬°¤½¥qªº[¯}²£µ¦²¤]²Ä¤T¦¸¦bªk®x¤W¥¢±Ñ¡C
www.sinklaw.com/mass-torts/tylenol/
¥Ø«eªº¬ã¨s¤wÃÒ¹ê¡A¹L¶qªA¥Î¹ï¤AñQ®ò°ò×ô¡]®õ¿Õµ¥«D³B¤èÃĤ¤¨Ï¥Îªº¤Æ¾Çª«½è¡^·|¾ÉP¨xŦ¶Wt²ü¹BÂà¨Ã³y¦¨¤£¥i°fÂ઺·l®`¡C
³\¦h¤HÁnºÙ¡A¾¨ºÞ¥LÌ¿í´`¤F²£«~»¡©ú¡A¦ý¦bªA¥Î®õ¿Õ«áÁÙ¬O¾D¨ü¤F¨x·l¶Ë¡C
³\¦h¤HÁnºÙ¡A¾¨ºÞ¥LÌ¿í´`¤F²£«~»¡©ú¡A¦ý¦bªA¥Î®õ¿Õ«áÁÙ¬O¾D¨ü¤F¨x·l¶Ë¡C
³\¦h¤HÁnºÙ¡A¾¨ºÞ¥LÌ¿í´`¤F²£«~»¡©ú¡A¦ý¦bªA¥Î®õ¿Õ«áÁÙ¬O¾D¨ü¤F¨x·l¶Ë¡C
¦pªG±z¦bªA¥Î®õ¿Õ«á¥X²{¨x·l¶Ë¡A±z¥i¯à¦³¸ê®æ¥[¤J®õ¿Õ²£«~»s³y°Ó McNeil Consumer Healthcare ªº¶°Åé«IÅv¶D³^¡C¨Ó¦Û³ìªv¨¯§J (George Sink) »«¦{¶Ë®`«ß®v¨Æ°È©Òªº«n¥dù¨Ó¯Ç¦{®õ¿Õ¶D³^«ß®v¥i¥HÀ°§U±z³B²z®×¥ó¡C
----------------------------------------------------------------------------------------
2017.2.23- ±j¥Í¤½¥q´N®õ¿Õ®¶D³^¹F¦¨©M¸Ñ
»«¦{¶O«°¡X®õ¿Õ®¶D³^®×¤w¹F¦¨·sªº©M¸Ñ¡C±j¥Í¤½¥qºX¤Uªº McNeill Consumer Healthcare ©ó 2017 ¦~ 2 ¤ë 10 ¤é¦P·N¥H¥¼´¦ÅSªºª÷ÃB¸Ñ¨M 200 ¦h°_®×¥ó¡C®Ú¾Úªk®x¤å¥ó¡A¸Ó¨óij¡§«Ø¥ß¤F¤@Ó¥þ²y¨p¤H©M¸Ñp¹º¡A¥H¸Ñ¨Mì§i°w¹ï McNeil ³Q§iªº®õ¿Õ¯Á½ß¡]µL½×¬O§_¤w´£°_¡^¡A¨Ã¥Bì§i¤w¦P·N³q¹L¸Óp¹º¸Ñ¨M¨ä®õ¿Õ¯Á½ß¡C¡¨
¶D³^«ß®v¾ß¨ìºj¡A¤£§âJNJ¥´¦¨¸ÁºÛ¤~©_©Ç!
---------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2021/6/26 ¤U¤È 04:06:47²Ä 1247 ½g¦^À³
¶D³^«ß®v¹ï±j¥Íªº¯Á½ß¥D±i:
Tylenol ªº³]p©M¾P°â¦³¯Ê³´¡A¨Ã¥B³B©ó¡§¦³¯Ê³´¥B¤£¦X²zªº¦MÀIª¬ºA¡¨
[¥i¨Ñ®ø¶OªÌ¨Ï¥Îªº²£«~À³¸Ó¨ã¦³¦X²zªº¦w¥þÃä»Ú]=½¦¨¥Õ¸Ü´N¬O:APAPªºªvÀø¾¯¶q»P¦w¥þ¾¯¶qªº¾¯¶q½d³ò¤Ó¯¶¡C
---------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2024/6/9 ¤W¤È 09:16:38²Ä 3790 ½g¦^À³
¤jÃļt¡u¤U¤£¤F¥x¡v§óÁ}Ãø¦a¤@¤Ñ¡AÅý¶D³^«ß®v¾ß¨ìºj¡A¯à´Á«Ý¤£µo¥Í¤j¨Æ???
¶D³^«ß®v/®ø¶OªÌ/¾ÇªÌ/µû½×®a/ªk©x¦b½æ³õ¬[¤W¬Ý¨£SAFETYNADOL(µL¨x¬r)¡A¹j¾ÀªºTylenol(¦³¨x¬r)
þ÷来¤]¤Ó¦³钱¤F¡A§Æ±æ¤]来个10e镁
¤îµhÃÄ¥«³õ³Q»{¬°¬OÄ~GLP-1´îªÎÃĤ§«áªº¤U¤@Ó¤d»õ¬ü¤¸ª÷Äq!!!
2023.3.2---§¨Ó»PConfoñ¸p¥~©P¯kµhªvÀøÃĪ«¡A¹w¥I 4000 ¸U¬ü¤¸¡A¨½µ{ª÷5.9 »õ¬ü¤¸¡C
-------------------------------------------------------------------------------
2023.6.5-¡u§Ú̦b°f¬y¦Ó¤W¡v¡G§¨Ó¬°¦ó¹Á¸Õ·s¤èªk¹ï§Ü¯kµh
¡u³o´N¬O§ÚÌ·Qnªº¡A¡v§¨Óº®u¦æ¾Pªø»¡¡C
....FDA §½ªøÃ¹§B¯S¡P¥d§Q¤Ò¡§´¿´N¹ªÀy»sÃĤ½¥q§ë¸ê¤îµhÃݵ¥X¹L¦³§Æ±æªºµû½×¡¨
´µ¬ì¨U¶©´µ°ò»¡¡G¡u³oÓ¦æ·~ªº«Ü¦h¤H¥u¬O°lÀH¼öªùªº¨Æª«¡C¡v¦ý³o¤w¸g±ß¤F10¦~¡C§A»Ýn°lÀH§A©Òª¾¹Dªº10¦~«á·|¬y¦æªº¨Æª«¡C°µ¨ì³o¤@ÂIªº³Ì¨Î¤è¦¡¬OÅý¥¦¦¨¥\¡A¼g¤U¥¼¨Ó¡X¡X³o´N¬O§Ú̦b³o¸Ì§V¤O°µªº¨Æ±¡¡C ¡v
2025.4.25-¤j¬~µP¡I§¨Ó¤fªA´îªÎÃÄorforglipron®ÄªG½VÀ£¿Õ©M¿Õ¼w ¥«Èöt¯}8000»õ¦¨·sÃĤý
©Ò¥H¦pªG§¨Ó¤£¦babcd¨½±¡A¥Nªíµ{«×¤Ó®t¬Ý¤£¤W²´¡K
简¨¥¤§¡A¬O负±¬Ý«Ý¡C°ß¤@´N¬Oabcd给¥X«击¥´脸ª©¤W¤£¬Ý¦nªº¦U¦ì¬Ý¾¡A¤]还¬Ý¦nªº¤@个¦¦©[°®
ÁÙ¨S¦¨¥\±ÂÅv¤½¥¬¡A¤Ñ¾å±oABCD¬O¨º®a?
¤£¦bþ÷来ªº¹p达¨½±??
================
2025.5.28-§¨Ó»¨ÂY¤Q»õ¬ü¤¸©ãª`¼ç¤O¤îµh·sÃÄ(«D¾~¤ùÃþ¤îµhÃĶ}µoªÌSiteOne)
....Ô¿ïÃĪ«§Y±N¶i¤J²Ä¤G´ÁÁ{§É¸ÕÅç¡A¸ÓÃĪ«³z¹LªýÂ_NaV1.8¶u³q¹D¨ÓªvÀø¯kµh¡C
¨Ó¡B¸¯Äõ¯À¥v§J¡B±j¥Í....¡C
2.¯kµhÃĪ«¬ãµoºÞ½u¥Dn¥Ñ¤p«¬¤½¥q¥D¾É¡A¦Ó¤p¤½¥q¬ãµoªº¯kµhÃĪ«³Ì«á´N¬O¸ò¤j¼t¦X§@¶}µo±ÂÅv
----------------------------------------------------------------------------------
·|û:ROGER588910148151µoªí®É¶¡:2025/5/14 ¤U¤È 10:04:39²Ä4068½g¦^À³
Top Analgesics Companies(¥þ²y³»¦y10®aÂíµhÃĤ½¥q)
½÷·ç¡B§¨Ó¡B¸¯Äõ¯À¥v§J¡B±j¥Í....
¦pªG§âÁ{§É[«e]¶}µo¥¢±Ñªº®×¥ó¤]¯Ç¤J²Îp¡A¯kµhÃþ·sÃĦ¨¥\¾÷²v®£Áͪñ0!
----------------------------------------------------------------------------------------
2023-The State of Innovation in Pain and Addiction¯kµh©M¦¨Å}»â°ìªº³Ð·s²{ª¬
§@ªÌ¡GDavid Thomas¡A¯S³\ª÷¿Ä¤ÀªR®v ©M¬d¼w¡P³¶ëº¸ ¥Íª«²£·~¤ÀªR
go.bio.org/rs/490-EHZ-999/images/BIO_The_State_of_Innovation_in_Pain_and_Addiction_2017_2022.pdf
¤îµhÃÄ0.7%¦¨¥\²v¤~¬OÃĪ«¶}µo³Ì¥i©Èªº¤j¿ú§|!!!
-----------------------------------------------------------------------------------
¸Õ°Ý0.7%¦¨¥\²v¡A¨º®a¤j¼t°ªºÞ¤£·|µn®ÉË©â¤F¤@¤f®ð¡A²D¤F¥bºI?
Àù¯gÃÄ5.1%%¦¨¥\²v / ºë¯«¯e¯fÃĪ« 6.2%%¦¨¥\²v.
2023¦~¥þ²y(DSP)¦a¶ë¦ÌªQÁC»Ä¶u¥«³õ³W¼Ò¹F11»õ¬ü¤¸¡C IMARC ¶°¹Î¹wp¡A¨ì 2032 ¦~¡A¥«³õ³W¼Ò±N¹F¨ì 15 »õ¬ü¤¸¡A2023-2032 ¦~´Á¶¡ªº½Æ¦X¦~¼Wªø²v¹wp¬° 4.20%¡C
----------------------------------------------------------------------------------
¥x·LÅéTLC599»ùÈ6.7»õ¬ü¤¸¡A¥i±¤¸Ñª¼¥¢±Ñ!
1. ¥x·LÅé¥H·L¯×Åé§Þ³N©µªøDSPÃþ©T¾JÃÄ¥N°Ê¤O¾Ç¨Ã¼W±jDSP©è¹F±w³Bªº¾÷²v----TLC599»ùÈ6.7»õ¬ü¤¸!
2022.6.13-¥x·LÅé«Å¥¬¡AºX¤U [ªø®Ä½wÄÀ]°t¤èÃö¸`ª¢¤îµhÃĪ« TLC599¡A»P°ê»Ú»sÃĤj¼t Endo
International plc ñq°Ó·~¤Æ¦X¬ù¡A¥x·LÅé±N¥iÀò±o¨½µ{¸Oª÷ 6.7 »õ¬ü¤¸
2.§¨Ó¥H2»õ¬ü¤¸º¥I¡B15.8»õùµ{ª÷Àò±o¦X§@¶}µoÅvTanezumab--->ªvÀø°©Ãö¸`ª¢ªº¤îµhÁ{§É¥¢±Ñ!
----------------------------------------------------------------------------------------
·|û:ROGER588910148151µoªí®É¶¡:2025/4/14 ¤U¤È 12:26:02²Ä4038½g¦^À³
³Ì·s¸ê®ÆÅã¥Ü¡A¤îµhÃÄ(0.7%)¤~¬O¬ãµo¦¨¥\²v³Ì§C! (Àù¯g 5.1%¡^
---------------------------------------------------------------------------------------
2016.7.6-¸Ñª¼¨Æ¥ó«á¬Ý·sÃĬãµoªº¦¨¥\²v
·sÃĬãµo¦¨¥\²v¸û§Cªº¤Ãþ¯e¯f¬°¡GÀù¯g¡]5.1%¡^¡Bºë¯«¯e¯f¡]6.2%¡^¡B¤ß¦åºÞ¯e¯f¡]6.6%¡^¡B¯«¸g¤º¬ì¯e¯f¡]8.4%¡^¡B¦ÛÅé§K¬Ì¯e¯f¡]11.1%¡^¡A
---------------------------------------------------------------------------
1.¥H¤W³æ¦ì:¤d»õ¬ü¤¸
2. 2013¦~§¨Ó¥H2»õ¬ü¤¸º¥I¡B15.8»õùµ{ª÷Àò±o¦X§@¶}µoÅvTanezumab(¤îµhÃÄ)¡C
§¨Ó¬Q¤Ñ¯{10»õ¬ü¤¸¦A¾Ô¤îµhÃÄ¥«³õ~
2024.6.21-¯kµh¥«场 ¤U¤@个¤d亿¡§ª÷矿¡¨
bydrug.pharmcube.com/news/detail/ef93507777141c6fa55cb443ae904df9
....Ô¿ïÃĪ«§Y±N¶i¤J²Ä¤G´ÁÁ{§É¸ÕÅç¡A¸ÓÃĪ«³z¹LªýÂ_NaV1.8¶u³q¹D¨ÓªvÀø¯kµh¡C
ªYÄ£预¦ôn¤L¿¤~¤H¨ú§A弃©O?¦pªG¤è«K¥i¥H给¤p§Ì¤@个参¦Ò
¼W¥[¤@¤U«H¤ß«¢
================================================
P´I¤§¹D¡A§Ö´N¬OºC¡AºC´N¬O§Ö¡AµLÄߪi°Ê¡A[°í«ù¦Û§Ú§PÂ_]
¬ü°êÂåÀø¶O«Ü°ª¶Q¡An«OÀI¤½¥q±Ç¿úÅý±wªÌÄ~ÄòªvÀø¡A±oÅã²{ÃĪ«Àø®Ä!
²Ä1¤ä¤W¥«ªºMASHÃĪ« Resmetirom ªvÀøªº¥Ø¼Ð±Ú¸s/Ä~Äò¥ÎÃÄ /°±¤îªvÀøªº¼Ð·Ç¡C
±M®a¤p²Õ«ØÄ³¡G¦b±w¦³ MASH/NASH ©M¤¤«×¦Ü«D¨xµw¤Æ±ß´ÁÅÖºû¤Æªº±wªÌ¤¤±Ò°Ê©MºÊ´ú Resmetirom ªº¹ê»ÚÁ{§ÉÀ³¥Î www.cghjournal.org/article/S1542-3565(24)00667-0/fulltext
...¦b MASH ¹ê¨Ò¤¤¡A¤þÓi»ÄÂà®ò酶 (ALT) §ïµ½ 17 U/L¡A»P¨ä¥L¬ã¨s¤¤ªº¨xŦ²Õ´¾Ç§ïµ½¦³Ãö¡C
¦pªG ALT ¨S¦³§ïµ½¡APDFF ´î¤Ö≥30% ¤´µM¥i¥H¹w´úÀø®Ä¡C
Y¥X²{¥H¤U±¡ªp¡A«hÄ~ÄòªvÀø¡G
®ò°òÂಾ酶±o¨ì§ïµ½¡]»P°ò½u©Î¥¿±`¤Æ¬Û¤ñ¡^¡C
®ò°òÂಾ酶éw¡A¦ý¦³¯e¯f§ïµ½ªº¨ä¥L¸ñ¶H¡]¨Ò¦p¡AMRI-PDFF ªº§ïµ½¡^¡C
------------------------------------------------------------------------------------
·|û:ROGER588910148151µoªí®É¶¡:2025/5/21 ¤W¤È 07:56:14²Ä4106½g¦^À³
¦å²M ALT ¤ô¥¤ñ[¯Ø®q¯À§Ü©Ê]©Î[Åé«]§ó¯à¹w´ú²Õ´¾ÇÅܤơA¨Ã¥B¥i¥H[§@¬°ªvÀøªº¦³®Ä«ü¼Ð]¡C
1.SNP-610°§C29.5 U/L
2.µL¨x¬rSNP-810Á{§É¸ÕÅç¨S¦³¥ô¦ó¨ü¸ÕªÌªºALT¶W¹L¥¿±`ȤWªº3¿¥H¤W¡AÅã¥Ü©Ò¦³¾¯¶q²Õ§¡¥¼¹F¨x¬r©Ê¼Ð·Ç¡C
¦³½ìªº¬O¡A¬ã¨sÆ[¹î¨ìCYP2E1§í¨î¥i¥H [¥[³t]AILI(APAP»¤¾É©Ê¨x·l¶Ë)±ß´Áªº [¨xŦ«ì´_]¡C
¦ýµ²½×¥u¬Oªì¨Bªº¡A¨xŦ¦A¥Í¥Íª«¼Ð°OªºÅܤƤ´¦³«Ý¶i¤@¨B½T©w¡C
---------------------------------------------------------------------------------
±N HSC ¥¿Å±qÅÖºû¤ÆÂà¦V¨xŦ«OÅ@¥i¯à¥Nªí¤@ºØ·s¿oªº¾ãÅéªvÀø¤èªk
CYP2E1§í¨î¥[³t¨xŦ«ì´_¡A±N¨x·l¶ËÂà¦V¨xŦ«OÅ@?(SNP-610»PSNP-630ÃĪ«?)
2025.5.22-¨x¬Pª¬²ÓM(HSC)¡G°·±d©M¯e¯fª¬ºA¤UªºÅ餺¥¿Å¡B«O¨x©MÅÖºû¤Æ
www.nature.com/articles/s41575-025-01068-6
ÀR¤îªºHSC³z¹L»P¤º¥Ö²ÓM¡B®w´¶¥±²ÓM©M¨x²ÓMªº³q°Tµo´§¨xŦúA¤¤ªºÃöÁä¥\¯à¡C
¬¡¤Æªº HSC ¥Nªí¥DnªºÅÖºû¤Æ²ÓMÃþ«¬¡A«P¶i¨xÅÖºû¤Æ¡B¨xµw¤Æ¡Bªù¯ß°ªÀ£©M¨xÀùªºµo®i¡C
¥Ø«eªºªvÀø·§©À¨Ã¥¼¦Ò¼{¨ì HSC ¥¿Å±qÅ餺¥¿Å©M«O¨x¥\¯à¦VÅÖºû¤Æ¥\¯àªºÂàÅÜ¡A¥i¥H§Q¥Î³o¤@ÂàÅܦP®É§í¨îÅÖºû¤Æ¨Ã«ì´_¨xŦÅ餺¥¿Å¡C
--------------------------------------------------------------------------------------
·|û:ROGER588910148151µoªí®É¶¡:2025/5/20 ¤U¤È 09:20:25²Ä4104½g¦^À³1½g
[ÄAÂЦʦ~»{ª¾]¬ã¨s--·|±a¨ÓÅå³ß¶Ü???
HSCs¥i³z¹LRSPO3©MWNT°T¸¹¬¡¤Æ¨Ó±±¨î¨xŦ[¤À°Ï]¡B[¥NÁÂ]¡B[·l¶Ë] ©M [¦A¥Í]
HSCs¤¤ [RSPO3] ªí²{»P¨x²ÓM¤¤[WNT¼Ð¹v°ò¦]CYP1A2©M CYP2E1]ÅãµÛ¬ÛÃö!
¦³½ìªº¬O¡A¬ã¨sÆ[¹î¨ìCYP2E1§í¨î¥i¥H [¥[³t]AILI(APAP»¤¾É©Ê¨x·l¶Ë)±ß´Áªº [¨xŦ«ì´_]¡C
§@¬°Á{§É¤W APAP ¹L¶qªº°ß¤@¸Ñ¬r¾¯¡ANAC ¤´¦³³\¦h¯ÊÂI¡A¨Ò¦pªø´ÁªvÀø«á¨xŦ«ì´_[©µ¿ð]
----------------------------------------------------------------------------------
·|û:ROGER588910148151µoªí®É¶¡:2025/5/20 ¤U¤È 09:20:25²Ä4104½g¦^À³
1½g[ÄAÂЦʦ~»{ª¾]¬ã¨s--·|±a¨ÓÅå³ß¶Ü???
HSCs¥i³z¹LRSPO3©MWNT°T¸¹¬¡¤Æ¨Ó±±¨î¨xŦ[¤À°Ï]¡B[¥NÁÂ]¡B[·l¶Ë] ©M [¦A¥Í]
HSCs¤¤ [RSPO3] ªí²{»P¨x²ÓM¤¤[WNT¼Ð¹v°ò¦]CYP1A2©M CYP2E1]ÅãµÛ¬ÛÃö!
----------------------------------------------------------------------------------
CYP2E1§í¨î¥i¥H[¥[³t]APAP»¤¾É©Ê¨x·l¶Ë±ß´Áªº[¨xŦ«ì´_]
APAP¹L¶qªº°ß¤@¸Ñ¬r¾¯NACªø´ÁªvÀø«á¨xŦ«ì´_[©µ¿ð]
CYP2E1§í¨î¥i¥H[¥[³t]»P[ÄAÂЦʦ~»{ª¾]¬ã¨s¦³ÃöÁp¶Ü????
¦³½ìªº¬O¡A¬ã¨sÆ[¹î¨ìCYP2E1§í¨î¥i¥H [¥[³t]AILI(APAP»¤¾É©Ê¨x·l¶Ë)±ß´Áªº [¨xŦ«ì´_]¡C
¦³½ìªº¬O¡A¬ã¨sÆ[¹î¨ìCYP2E1§í¨î¥i¥H [¥[³t]AILI(APAP»¤¾É©Ê¨x·l¶Ë)±ß´Áªº [¨xŦ«ì´_]¡C
¦³½ìªº¬O¡A§ÚÌÆ[¹î¨ì si- Cyp2e1 LNPs ¥i¥H¥[³t AILI ±ß´Áªº¨xŦ«ì´_¡C¦ýµ²½×¥u¬Oªì¨Bªº¡A¨xŦ¦A¥Í¥Íª«¼Ð°OªºÅܤƤ´¦³«Ý¶i¤@¨B½T©w¡C
§@¬°Á{§É¤W APAP ¹L¶qªº°ß¤@¸Ñ¬r¾¯¡ANAC ¤´¦³³\¦h¯ÊÂI¡A¨Ò¦pªø´ÁªvÀø«á¨xŦ«ì´_©µ¿ð¡B¤£¨}G¸z¹D¤ÏÀ³ ¡C¥»¬ã¨sªí©ú¡A³z¹LLNP»¼°eªº°w¹ïCyp2e1ªºsiRNA¥i¥H´î»´APAP¹L¶q¤Þ°_ªº«æ©Ê¨x·l¶Ë¡A¬°®¾±ÏAPAP¤¤¬r´£¨Ñ¤F¤@ºØ·sªºªvÀøµ¦²¤¡A©Ý¼e¤FRNAi¦b«æ©Ê¨x¯f¤¤ªºÀ³¥Î¡C
-------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2022/5/28 ¤U¤È 05:22:04²Ä 2031 ½g¦^À³
ªYÄ£¥²nÅçÃÒ³o½g½×¤å´£¥Xªº¾÷¨î:SNP610(CYP2E1§í¨î-->¤º·½©Ê¥NÁª«ÅãµÛ¼W¥[-->¿E¬¡ PPAR£\-FGF21)
¤Úµá¯S»¡¡G¡u¿ú·|±q¨S¦³@¤ßªº¤H¤â¤¤¡AÂಾ¨ì¦³@¤ßªº¤Hªº¤â¤¤¡C¡v¦¨¥\³ÌÃø¼õªº®É¨è¡A´N¬O¦¨¥\«eªº¨º¤@¨è¡C
¨È°¨»¹³Ð¿ì¤H¨©¦õ´µ´¿°Ý¤Úµá¯S¡G¡u§Aªº§ë¸ê¤èªk²³æ¡A¬°¤°»ò´X¥G¨S¤H¯à½Æ»s©O¡H¡v
¤Úµá¯S¦^µª¡G¡u¦]¬°¨S¦³¤HÄ@·NºCºCÅܱo´I¦³¡C¡v
--------------------------------------------------------------------------------------
¡u¦]¬°¨S¦³¤HÄ@·NºCºCÅܱo´I¦³¡C¡v---ºC´N¬O§Öªº¶ø¸q¡A«ÂI¦b§ä[¹ïªº¤½¥q]ªø´Á§ë¸ê~
[¿W®a±ÂÅv]©x¥q¨S§¹¨S¤F¡AÅý§Úµh¥¢µo¤j°]¾÷·|~
2025.5.19-AOP©x¥q®× ÃĵØÃÄ´£ºM¾P¥òµô Âù¤è¡uªk°|¨£¡v
----------------------------------------------------------------------------------------
±i¶vÚ¬»{ÁÊ256±i¡A»{Áʪ÷ÃB¬ù6,000¸U¤¸
¥Î¦o·í°Ñ¦Ò¡A«¥±i¼Æ¤ñ¦o¦h¡Aª÷ÃB¤ñ¦o¤Ö¡A¦]¬°¨º³õ©x¥q§Úµh¥¢µo¤j°]¾÷·|~
¤µ¤Ñ³o¤½¥q¦b¥²´Iºô¶R»ù180¤W¤U¡A½æ»ù220¤W¤U(¹wp500¤¸¥H¤W¤H¨ú§Ú±ó)¡C
¶R¤J«á¦³1/2ªº®É¶¡¡AªÑ»ù´N¬O1±ø¾î½u¡Aªñ´X¦~¨ÓÀ禬Àò§Q¶}©lÃzµo~
¥Ø«e¤j·§¬O40¿³ø¹S²v(¤wÃi±oºëºâ)¡A¹wp100¿³ø¹S²v«á¤H¨ú§Ú±ó¡C
-----------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2022/4/24 ¤U¤È 05:38:46²Ä 1919 ½g¦^À³
¤µ¤Ñ¤â¤W³o®a¥¼¤W¥«¤½¥q¦b¥²´Iºô¶R»ù128~129¡A½æ»ù150¡C(¹wp250¤¸¥H¤W¤H¨ú§Ú±ó)
....9¦~«e«Ü¦h¤H¥ÎÁ«·l»ù½æ¥X¡A«Ü¦nij»ù¦b¤Q¶ôªì¦¨¥æ¡C
·|§ë¸ê³o®a¤½¥q¬Oª¾¹D¨ä²£«~ªùÂe·¥°ª(¥xÆW«ÜÃø¦A¦³²Ä2®a¥X²{)¡C
·|û¡GROGER588910148151 µoªí®É¶¡:2021/6/20 ¤W¤È 10:58:06²Ä 1226 ½g¦^À³
...¦pªG¤£¬O5¦~«e»P¤@¦ì¬ãµo¸g²z²á¤Ñ«á³B²zX«ùªÑ(¿ù»~ªº¨M©w)¡A²{¦b¤â¤WX±i¡C
---------------------------------------------------------------------------------------
·|û:ROGER588910148151µoªí®É¶¡:2024/8/6 ¤W¤È 07:30:55²Ä3926½g¦^À³·|û¡GROGER588910148151 µoªí®É¶¡:2024/7/9 ¤U¤È 05:06:23²Ä 3890 ½g¦^À³
¡§1¦~5¿ªÌ¦p¹L¦¿¤§ÃV¡B5¦~1¿ªÌ«o¹éY¨°¬P¡¨(®©¤£¥X? ¦^·Q¤@¤U°ê¹©¿ÄÂ_¤W300.....)
§Ú¬J¬ÝªÅ´N¤£°µ¦h¤]¤£°µªÅ¡A°O¤£²M¬O¨º¦~¼o¤F¿Ä¸ê¨é¸ê®æ¡C
P´I¤§¹D¡A§Ö´N¬OºC¡AºC´N¬O§Ö¡AµLÄߪi°Ê¡A[°í«ù¦Û§Ú§PÂ_]
²×©ó¦b¤µ¦~ªÑ东会¤ÞÃzÅå¤Ñ«ã¤õ???会¤£会¤]¥X¤@¤¿¶û???¦Ó¤Ï¦¨Ã¹»«º~???
¤½¥q过¤Ó²n´N¬O没¦³ªÑ东当场¬~脸¡A¤£过¤]´N¬O¨C¦~¬~¤@¦¸¡A¤S²n²n¦ÛªÎ¤@¦~¡C
学学³¢¸³呛ªÑ东¡A§â¤â¤Wªº¤@¿¥[ɲ买¦^¡A¬Ò¤j欢³ß
=================
¬ü°êÂåÀø¶O¤§°ª¡A¥Á²³¥Ó½Ð¯}²£ªÌ¡A¹L¥b¤ñ¨Ò¬O¦]¬°ÂåÀø±b³æªºì¦]¡A²×©ó¦b¥h¦~¤ÞÃzÅå¤Ñ«ã¤õ¡A¤¿¶û¤Ï¦¨Ã¹»«º~!
2024.12.16-¬ü°êÂå®våªRì¦]¡GÂå«OÀsÀY CEO ¾Dºj±þ¡A¤¿¶û«o³Q·í¦¨¡u¥þ¥Á^¶¯¡v¡H
crossing.cw.com.tw/article/19536
2024.12.16-¬ü°êÂå®våªRì¦]¡GÂå«OÀsÀY CEO ¾Dºj±þ¡A¤¿¶û«o³Q·í¦¨¡u¥þ¥Á^¶¯¡v¡H
crossing.cw.com.tw/article/19536
[«D³B¤èÃÄ]¹ï¤AñQ®ò°ò×ô¹L¶q¦Ó³y¦¨ªº¨xŦ·l®`¡A¤£¬O¤@Ó[ÄY«ªº¤½¦@½Ã¥Í°ÝÃD]?
§Ú¤£ª¾¹D¡u¤½¦@½Ã¥Íªº»ùÈ¡v¦h¤Ö? $$$¥Ñ°ê»Ú¤jÃļt¥X¤â´¦¾å!!!
---------------------------------------------------------------------------------
2011¦~¹w§i±Ä¨ú±¹¬I:
¬ü°ê¹«~ÃĪ«ºÞ²z§½(FDA¡^¥¿¦b±Ä¨ú±¹¬I°§C[³B¤èÃÄ]²£«~¤¤¹ï¤AñQ®ò°ò×ôªº³Ì¤j¾¯¶q³æ¦ì±j«×¡C³o¶µÅܧó±N´£¨Ñ§ó¤jªº [¦w¥þÃä»Ú]¡A [¦³§U©ó¨¾¤î¦]¹ï¤AñQ®ò°ò×ô¹L¶q¦Ó³y¦¨ªº¨xŦ·l®`¡A³o¬O¤@ÓÄY«ªº¤½¦@½Ã¥Í°ÝÃD]¡C¸Ó³qª¾¸ÑÄÀ¤F°§C¾¯¶q³æ¦ì±j«×ªºì¦]¡A¨Ã´yz¤F FDA ¦p¦ó°w¹ï¶W¹L·sªº³Ì¤j¤ù¾¯©Î½¦Ån±j«×ªº¤w§åã³B¤èÃIJ£«~¹ê¬I¸Ó³qª¾¡C FDA ÁÙn¨D¹ï§t¦³¹ï¤AñQ®ò°ò×ôªº³B¤èÃIJ£«~ªº¦w¥þ¼ÐÅÒ¶i¦æ×§ï¡A¥]¬A¼W¥[·sªº¶Â®ØÄµ§i¡A¥H±j½Õ¦³Ãö¨x·l¶Ë·ÀIªº·s¦w¥þ¸ê°T¡C
----------------------------------------------------------------------------------------
2014¦~¤½§i-FDA n¨DÁ{§ÉÂå¥Í¨î¤AñQÓi×ôªº³B¤è
FDA «ØÄ³Á{§ÉÂå¥Í°±¤î¶}¥ß©M°tµo¨C¾¯§t¦³¶W¹L 325 ²@§J¹ï¤AñQ®ò°ò×ôªº½Æ¤èÃĪ«¡C
2022.3.4--¬ü°ê¬rª«¤¤¤ßªº¨àµ£¦Û±þ¨Æ¥ó³ø§i
.¹ï¨Ó¦Û°ê®a¬rª«¼Æ¾Ú¨t²Îªº¼Æ¾Ú¶i¦æ¤F¤ÀªR¡A¥H¤F¸Ñ 2015 ¦~¦Ü 2020 ¦~¶¡©Ò¦³ºÃ¦ü¨àµ£¦Û±þ²v©MÀW²vªºÁͶաC¤ÀªR¤F 514,350 ¦W¨àµ£ºÃ¦ü¦Û±þ¨Æ¥ó¡A¨ä¤¤ 10 ¦Ü 12 ·³¨àµ£ªººÃ¦ü¦Û±þ²v¼W´T³Ì¤j (109.3%¡Ap = 0.002)¡C13 ¦Ü 15 ·³ (30.3%, p < 0.001) ©M 16 ¦Ü 19 ·³ (18.1%, p < 0.05)¡C³Ì±`¥Îªºª«½è¬O¥¬¬¥ªâ©M¹ï¤A酰®ò°ò×ô¡A¹ï¤A酰®ò°ò×ôªº±µÄ²²v¼W´T³Ì¤j.....
--------------------------------------------------------------------
OTC[«D³B¤è]ªºAPAPªº¦í°|²v¹ê»Ú¤W«D¦ý¨S¦³´î¤ÖÁÙ[¼W¥[][¼W¥[]---
FDA«ç»ò¸Ñ¨M¤W±2Ó¿S¤â°ÝÃD? ³Ì²³æ¦³®Ä¤è¦¡:³]ªkÅý«D³B¤è¶q¾P°â¶q¤U°(³B¤èÃļƶq³Ñ1/3)¡A¦Ü©ó¾P°âÃB¤j´î¨º¬O¤jÃļtªº¨Æ!
---------------------------------------------------------------------------------
OTC[«D³B¤è]ªºAPAPªº¦í°|²v¹ê»Ú¤W«D¦ý¨S¦³´î¤ÖÁÙ[¼W¥[][¼W¥[]---¼Æ¾Ú¤w¹G¢FDA¹ï[«D³B¤è]APAPÄY¥[ºÞ¨î¡A ¤jÃļt¾P°âÃB·|¤£´î¤Ö¤]¬O¨£°¤F!
¦@¦P§@ªÌ§Æ±æ FDA±À¥X·sªº¤½¦@½Ã¥Í¬Fµ¦(¦p¦P^°ê)¨Ó¨î¤AñQÓi×ô¨x·l¶Ë
1.¯kµh¬O¥þ²y¤½¦@½Ã¥ÍªºÀu¥ý¨Æ¶µ
bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-11-770
...±N¯kµh²z¸Ñ¬°¤½¦@½Ã¥ÍÀu¥ý¨Æ¶µ¦³§U©ó¸ÑÄÀ¨ä»P°·±dªºªÀ·|©M¸gÀÙ¨M©w¦]¯Àªººò±KÁpô¡C
2.«D¦ÛµMì¦]¾ÉP¤£¥µ¥Åý§Ú̥ͯf¶Ü¡Hwww.youtube.com/watch?v=aTIPBQMpF9Y
----------------------------------------------------------------------------------------
·|û:ROGER588910148151µoªí®É¶¡:2024/6/7 ¤U¤È 06:10:56²Ä3778½g¦^À³
...¦¶³Í¥Á»¡¡A¥@¬É¯Å¤jÃļt³£¬O¥H¡u¤½¦@½Ã¥Íªº»ùÈ¡v¬°³Ì¤j©v¦®¡A¦]¦¹¥¼¨Ó±N±Ä«D±MÄÝ¡B¤À°Ï±ÂÅvµ¦²¤¡A²{¶¥¬q±ÂÅvºN¦¡¤£³]±Ä¨ú¶}©ñºA«×¡ASNP-810¤]¤w¨ú±o¬ü°êOTC¡]«D³B¤èÃÄ¡^¥«³õ¾P°âÅv¡C
----------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2024/6/7 ¤U¤È 05:55:52²Ä 3776 ½g¦^À³
FDA¶}îÔ¤F!
±µ¤U¨Óªº¤T¦~¤º¸Ñ¨Mªºp¹º±MµÛ¬¡°Ê(2020.3.27-¤t´¶Ã±¸p¡m«D³B¤èÃĦw¥þ¡A³Ð·s©M§ï²ªk®×¡n
...FDA±N¥LÌÃö©ó±Nþ¨Ç¬¡°Ê¦C¤J¹w´úªº¨Mµ¦´yz¬°³q±`¥H [¤½¦@½Ã¥Í] Àu¥ý¨Æ¶µ¬°«ü¾É¡v....
----------------------------------------------------------------------------------------
·|û:ROGER588910148151µoªí®É¶¡:2024/6/6 ¤W¤È 07:00:59²Ä3770½g¦^À³
2023.3.20--¥²¶·°µ§ó¦hªº¤u§@¨Ó´î¤Ö¹ï¤AñQ®ò°ò×ôªº¨x¬r©Ê(«D³B¤èªº¦í°|²v«D¦ý¨S¦³´î¤ÖÁÙ¼W¥[ ¼W¥[ ¼W¥[)
...¡m¬ü°êÂå¾Ç·|Âø»x¡n(JAMA) ³Ìªñµoªí¤F¤@¶µ¬ã¨s¡A±´°Q¤F³o¶µ³W©w¹ï¤½¦@°·±dªº¼vÅT¡A¨Ã±o¥Xµ²½×.....
¦Û 2011 ¦~¥H¨Ó¡A¦]³æ¥Î¹ï¤AñQ®ò°ò×ô²£«~(«D³B¤èÃÄ)ªº¬r©Ê¦Ó¦í°|ªº¤H¼Æ³v¦~¼W¥[¡C
µ²½×:1.FDAªº±j¨î¤âªk¥u¹ï³B¤èÃĦ³®Ä¡AOTC[«D³B¤è]ªºAPAPªº¦í°|²v¹ê»Ú¤W«D¦ý¨S¦³´î¤ÖÁÙ[¼W¥[][¼W¥[]¡C
2.¦@¦P§@ªÌ§Æ±æ FDA±À¥X·sªº¤½¦@½Ã¥Í¬Fµ¦(¦p¦P^°ê)¨Ó¨î¤AñQÓi×ô¨x·l¶Ë¡A¦ý¬Û«H³Ì¦nªºªø´Á¿ï¾Ü¬O¶}µo§ó¦w¥þªº¤îµhÃÄ¡C
....Efimosfermin±NÅãµÛÂX¥R§Ú̪º¨x¯fÃĪ«¬ãµo²£«~½u¡A¨Ã¬°§ÚÌ´£¨Ñ¶}µo¤@ºØ·sªº¼ç¦b¦PÃþ³Ì¨ÎÃĪ«ªº¾÷·|¡A¥i±æ©ó2029¦~º¦¸±À¥X¡C¥¦»P¥¿¦b¶}µo¥Î©óªvÀøALD©MMASHªºGSK¡¦990¬Û»²¬Û¦¨¡A¬°GSK´£¨Ñ¤F¶}µo [³æÃĪvÀø] ©M¼ç¦b [¦@¦PªvÀø] ¥H§ïµ½¯f±wªvÀø®ÄªGªº¿ï¾Ü¡C¡v
------------------------------------------------------------------
FGF21°fÂà[¨xµw¤Æ]ªº¯e¯fº¦¸ÃÒ¾Ú(GSK¯{20»õ¬ü¤¸ªºì¦])---²Å¦X§Ú2023¦~»¡F4(ªì´Á¨xµw¤Æ)¤~¬O³Ì¤jªºÂê÷®w!
--------------------------------------------------------------------------------------
¿Õ©M¿Õ¼wªvÀø²Õ©M¦w¼¢¾¯²Õ¤§¶¡ªº [ÅÖºû¤Æ]¶¥¬q§ïµ½¨S¦³®t²§¡C